A BPC-157 capsules COA looks different from the injectable-format document most researchers have seen. The active compound is the same 15-amino-acid peptide, but the capsule format introduces additional quality checkpoints — fill weight uniformity, dissolution, and mass per unit — that a lyophilized vial COA doesn’t cover. Knowing what to look for in that document before you place an order takes the guesswork out of vendor selection.
Identity and Purity
The top of a capsule COA names the product, batch or lot number, and the testing date. Below that is the identity and purity section, which is the most important part of any research peptide document.
Identity testing uses HPLC with UV detection or mass spectrometry. The lab confirms the molecular weight of BPC-157 — 1419.53 Da for the free acid form — and verifies that the chromatographic profile matches the reference standard. A COA that lists identity as “conforms” without supporting molecular weight data or a retention time value is underinformative. Request the full analytical report, not just the summary page.
Purity is expressed as a percentage of area under the HPLC curve. For research-grade BPC-157 capsules, the purity figure should read >99%. Anything below 98% falls outside the accepted range for research-grade material. This purity figure applies to the API (active pharmaceutical ingredient) only and does not reflect inactive excipients like microcrystalline cellulose or magnesium stearate, which are listed separately on the specification sheet.
Mass Per Capsule
This section does not appear on injectable vial COAs. Each capsule contains a stated quantity of BPC-157 — commonly 500 mcg. The COA should confirm that the measured mass per capsule falls within acceptable tolerance, typically ±5% of the stated amount.
If the COA reports total batch weight alongside capsule count rather than per-unit mass, you can calculate it: divide total peptide mass in mcg by the number of capsules. A well-formatted report from Freedom Diagnostics or Horizon Analytical will list the per-capsule figure directly rather than requiring that calculation. If the supplier cannot provide per-capsule mass data, the COA is incomplete.
Capsule Uniformity
Content uniformity testing samples a set of capsules from the batch — typically 10 units — and confirms that each contains peptide within a defined range of the stated dose. Acceptable variation across units is ±10% per USP <905> guidelines, though suppliers targeting consistent research-grade material often work to tighter internal specifications.
This test matters for study reproducibility. Inter-capsule variability introduces noise into dose-response protocols. If your experiment runs on a fixed schedule across multiple animals or cell preparations, fill consistency is a controlled variable you want confirmed in the COA, not assumed.
Dissolution
Some COAs for capsule formulations include dissolution data, which measures what percentage of the active compound releases into solution within a defined time window — typically 30 or 45 minutes. This reflects how reliably the capsule delivers the API in aqueous conditions, which is relevant for in vitro applications where researchers dissolve capsules before use in cell-based assays.
A result of ≥85% dissolved at Q45 minutes is a standard benchmark for immediate-release formulations. Not every COA includes this test. If dissolution data matters for your protocol — say you’re running a solubilization step before application — confirm the data is available before ordering.
Bacterial Endotoxin Testing
Every research-grade peptide COA should include results from bacterial endotoxin testing. This screen confirms the material is free from lipopolysaccharides shed by gram-negative bacteria during synthesis — a risk that applies to capsule and injectable formats alike, since contamination can occur at the API stage before encapsulation.
The accepted limit for research compounds is typically <1 EU/mg, though some in vitro applications set stricter thresholds. Look for a numerical result alongside the specification, not just a “pass” notation. A COA that reports only “within limits” without numerical values offers less traceability than one that shows the full assay result.
Freedom Diagnostics and Horizon Analytical, the third-party labs used for Blank Peptides’ material, include numerical endotoxin values with the assay methodology documented — LAL kinetic turbidimetric testing is standard for this class of compounds.
Excipients and Capsule Shell
The COA or accompanying spec sheet should list inactive ingredients. Common excipients include microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate. The capsule shell is typically size-0 hydroxypropyl methylcellulose (HPMC), which suits researchers who prefer to avoid gelatin for experimental consistency or other reasons.
Excipient identity doesn’t affect peptide purity, but it can matter for in vitro study design if the compounds could interfere with the assay readout. Cross-reference with your cell culture conditions before planning.
What a Complete COA Signals
A complete BPC-157 capsule COA includes: identity confirmation with molecular weight, purity >99% by HPLC, mass per capsule within stated tolerance, content uniformity across the sampled batch, dissolution data (when applicable), numerical bacterial endotoxin results, and full excipient disclosure. Missing any of these — particularly the per-capsule mass and endotoxin data — means the document is partial.
Researchers sourcing BPC-157 in injectable format alongside capsule presentations will notice that the injectable COA omits fill uniformity and dissolution tests but adds reconstitution specifications. Both formats should include purity >99% and endotoxin screening as baseline requirements, regardless of format.
Partial COA documentation is common among lower-quality suppliers. Before placing any first order, request the complete document and verify that lot-specific data — not a generic template — is what you’re receiving. A supplier unwilling to provide it is a reliable signal to look elsewhere.
FAQ
What purity should a BPC-157 capsule COA show?
Research-grade BPC-157 capsules should show purity >99% by HPLC. This applies to the active peptide only and is separate from any excipient disclosure. COAs reporting purity between 95% and 98% are below the standard threshold for research-grade material; anything lower than that represents significant impurity that could compromise experimental results.
Why does a capsule COA include tests that a vial COA doesn’t?
Capsule formulations introduce variables that don’t exist in lyophilized powder or vial presentations. Fill weight uniformity, mass per capsule, and dissolution all depend on the encapsulation process rather than on the peptide synthesis itself. A researcher using injectable BPC-157 controls preparation variables directly; a researcher using capsules relies on the supplier to have done it correctly at scale, which is why the additional tests are warranted.
How does KPV’s COA compare to a BPC-157 capsule COA?
KPV is a tripeptide that can be formulated in capsule or lyophilized formats. Its COA follows the same analytical framework — HPLC purity, identity confirmation, and bacterial endotoxin testing — because the testing methodology is standardized across research peptides regardless of the specific compound. Compound-specific values like molecular weight and reference standard will differ, and any capsule-format KPV COA would include the same fill uniformity and per-unit mass sections that a BPC-157 capsule COA does.
All products discussed are for laboratory research use only and are not for human or veterinary use.